<DOC>
	<DOCNO>NCT00160030</DOCNO>
	<brief_summary>The primary objective study assess feasibility ( completion full treatment ) arm assess endoscopic complete response rate arm . The secondary objective study assess toxicity profile arm use National Cancer Institute-Common Toxicity Criteria ( NCI-CTC ) scale ( V.3 ) .</brief_summary>
	<brief_title>Study Comparing Radiochemotherapy With Folfox 4 Regimen 5FU-Cisplatin Patients With Inoperable Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients : Histologically proven adenocarcinoma , squamous cell adenosquamous carcinoma esophagus Inoperable esophageal carcinoma ( disease status : T , N0 N1 , M0 M1a ) surgical contraindication condition No prior treatment esophageal cancer ( surgery , laser , chemo radiotherapy ) Oesophageal dilatation allow treatment , prior esophageal prosthesis allow Peripheral neuropathy &lt; = NCICTC grade 1 Age &gt; = 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) &lt; = 2 Sufficient ( oral gastrostomy ) calorific intake ( &gt; 1000 Kcal/m2/day ) Life expectancy &gt; = 3 month Adequate bone marrow reserve , normal renal liver function : Neutrophil count &gt; = 1500/mm³ Platelet count &gt; = 100,000/mm³ Hemoglobin &gt; = 10 g/dl ( transfusion , necessary ) Creatinine level &lt; = 1.5 x upper normal limit institutional value ( ULN ) Total bilirubin level &lt; 1.5 x ULN ALT/AST &lt; 2.5 x ULN Prothrombin time &gt; = 60 % Laboratory value obtain week precede study entry Signed informed consent ( prior study procedure ) Start treatment within 28 day inclusion . Metastatic disease except third upper cervical esophagus tumor regional node , third low esophagus tumor celiac node ( M1a ) Multiple carcinomas esophagus Small cell undifferentiated carcinoma esophagus Complete dysphagia ( grade 4 NCICTC ) ; patient exclusive parenteral nutrition . Weight loss &gt; 20 % normal body weight Pregnant breastfeed woman Fertile patient use adequate contraception Peripheral sensitive neuropathy functional impairment Auditory disorder History prior malignancy ( cure non melanoma skin cancer , cure cervical carcinoma situ stage I II node negative head neck cancer cure &gt; 3 year ago ) Prior cervical , thoracic abdominal radiotherapy field overlap propose oesophageal radiotherapy field Tracheooesophageal fistula invasion tracheobronchial tree Previous myocardial infarction ( inferior equal 6 month ) . Patients previous myocardial infarction superior 6 month , could include : transient ischemia show thallium myocardial scintigraphy favourable advice chemotherapy obtain cardiologist . Other serious illness medical condition ( symptomatic coronary disease , leave ventricular failure uncontrolled infection ) Arterial disease stage II IV accord Leriche Fontaine classification Treatment experimental drug participation another clinical trial within 30 day study screen Concurrent treatment anticancer therapy Concurrent treatment phenytoin yellow fever vaccine ; geographical , social psychological circumstance prevent regular followup . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>